drug_type
RELEVANT_DRUG
intervention_type
Cellular immunotherapy (CAR T cells)
drug_description
Allogeneic CD9-directed UCAR-T cells; genetically modified T cells engineered with a CAR targeting CD9. Administered by cell infusion to recognize CD9+ malignant plasma cells and induce T-cell cytotoxicity and cytokine release.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Allogeneic, gene-edited T cells engineered with a CD9-specific chimeric antigen receptor bind CD9 on malignant plasma cells, triggering CAR signaling that activates T-cell cytotoxicity and cytokine release to lyse target cells.
drug_name
CT7590 (CD9-UCAR-T)
nct_id_drug_ref
NCT05822037